Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial.

Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF- and TGF- in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial Mol Clin Oncol 13:29, 2020; DOI: 10.3892/mco.2020.2099 Following the publication of this article, the authors have realized that, in the Materials and methods section, in the subsection ' I Protocol i ' on p. 2, the second and the final sentences of the second paragraph contained errors: The text in the second paragraph of this subsection should have been written as follows: 'RJ was procured from Yamada Agriculture Center Inc (Okayama, Japan). RJ and placebo were prepared as capsules containing B 800 b mg RJ and starch, respectively. [Extracted from the article]